Regeneron Pharmaceuticals (NASDAQ:REGN) will be issuing its quarterly earnings data before the market opens on Wednesday, February 6th. Analysts expect the company to announce earnings of $5.10 per share for the quarter.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The company had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same quarter last year, the company earned $3.99 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.8% compared to the same quarter last year. On average, analysts expect Regeneron Pharmaceuticals to post $19 EPS for the current fiscal year and $19 EPS for the next fiscal year.
Regeneron Pharmaceuticals stock opened at $425.40 on Tuesday. Regeneron Pharmaceuticals has a 52 week low of $281.89 and a 52 week high of $431.32. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.04 and a quick ratio of 3.30. The stock has a market cap of $46.55 billion, a P/E ratio of 31.72, a price-to-earnings-growth ratio of 1.85 and a beta of 1.27.
In other news, Director Joseph L. Goldstein sold 1,791 shares of the business’s stock in a transaction that occurred on Thursday, January 10th. The stock was sold at an average price of $410.00, for a total transaction of $734,310.00. Following the completion of the sale, the director now owns 14,114 shares in the company, valued at $5,786,740. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Christopher R. Fenimore sold 1,848 shares of the business’s stock in a transaction that occurred on Thursday, December 20th. The stock was sold at an average price of $358.97, for a total value of $663,376.56. Following the sale, the vice president now owns 9,871 shares of the company’s stock, valued at approximately $3,543,392.87. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,645 shares of company stock valued at $1,399,980. Corporate insiders own 12.42% of the company’s stock.
A number of equities analysts recently commented on the company. TheStreet upgraded Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, January 17th. BidaskClub upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, January 7th. Cowen reiterated a “hold” rating and set a $385.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, January 7th. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 5th. Finally, Guggenheim upgraded Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $461.00 price target for the company in a report on Friday, January 4th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $404.11.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.fairfieldcurrent.com/news/2019/02/05/regeneron-pharmaceuticals-regn-scheduled-to-post-quarterly-earnings-on-wednesday.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: Stock Symbols and CUSIP Explained
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.